KineMed, Pfizer deal

The companies partnered to use KineMed’s kinetic biomarker technology to discover and develop biomarkers. The companies will collaborate on the discovery, and the pharma will be responsible for development and commercialization of resulting biomarkers or companion diagnostics. The pharma said the deal spans multiple therapeutic areas but primarily will target cardiovascular, metabolic and neurology areas. Pfizer said it has not selected targets yet. ...